EZZ Life Science Holdings ASX:EZZ

Yesterday, EZZ Life Science held its Annual General Meeting. Chair Glenn Cross provided shareholders with a comprehensive overview of FY24, outlining the company’s strategic direction and achievements. A key highlight was the exceptional sales performance during the 11.11 Shopping Festival, with $5.91 million in revenue—a remarkable 84% increase compared to last year. Read the full Chair’s address to shareholders here: https://lnkd.in/gF5KA-hg

We are excited to announce that EZZ Life Science Holdings ASX:EZZ has been included in the MSCI Inc. World Micro Cap Index. This milestone reflects our growth and commitment to bringing innovative health solutions to a global audience. Being part of this index not only amplifies our visibility but also marks a significant step towards broader market recognition for EZZ. Read more about our inclusion in the MSCI World Micro Cap Index here: https://lnkd.in/gMCgrs6U

EZZ Life Science Holdings ASX:EZZ has declared a fully franked final dividend of $0.02 per share, marking a positive step for its investors. Read More https://lnkd.in/gR4HXp7z #EZZLife, #dividendAnnouncement, #shareholders, #genomicLifeScience

EZZ Life Science is pleased to announce its results for Q1 FY25.  Receipts from customers during China’s retail off-season totalled $15.4m, up 128.4% on the prior corresponding period last year.  MORE: https://lnkd.in/ggTNqEhz

EZZ Life Science Holdings ASX:EZZ is very excited to be shortlisted again this year as a 2024 Finalist in the Health and Life Science category of the Australian Growth Company Awards!

📢 AusBiotech is thrilled to welcome 17 new members who have joined our thriving life sciences community between July and September. AusBiotech has always been for its members. Built by our members, to be the national voice of our sector we are proud to support our member's growth and leverage our national convening power to shape policy, foster knowledge sharing, and collaborate to advance life sciences in our country. Together, we work to help our members thrive. We’re delighted to announce new AusBiotech members including: Agriculture Victoria Services Pty Ltd, Atticus Medical, BlinkLab Limited, CAD-IT Australia Pty Ltd, Cambium Bio, Douglas Pharmaceuticals, Evaluate Consulting, Evithé Biotechnology, EZZ Life Science Holdings ASX:EZZ, Global Pharma Solutions, JAG Process Solutions PTY LTD, Kurraba Group, Lachesis Biosciences, Nova Eye Medical, PureCDM, Syngene International Limited, VVMF - Viral Vector Manufacturing Facility. Our warmest welcome to our 17 new members. We're so pleased you have joined AusBiotech and our community of more than 3000 life sciences leaders. We can't wait to work with you and your teams. Find out more about AusBiotech's new members at https://lnkd.in/eFTy-Qjr #AusBiotech #LifeScience

Did you know China is home to an impressive 300 million tennis enthusiasts? EZZ is excited to announce a three-year #sponsorship with Tennis Australia as a Regional Partner for the #AustralianOpen commencing in 2025. This collaboration will help strengthen EZZ’s presence by promoting our leading health products while engaging with a wider audience who share a passion for tennis across #China and #SoutheastAsia. READ MORE: https://lnkd.in/guC62Vhk

📢 Strengthening Australia-Hong Kong health and investment ties AusBiotech was pleased to be invited to participate in a HealthTech Roundtable and Business Luncheon with the Hong Kong Government’s Financial Secretary, Mr. Paul Chan, and members to discuss growth opportunities for Australian biotech in Hong Kong and Asia. The roundtable, organised by Hong Kong Economic Trade Office and InvestHK, attracted attendees from a wide range of stakeholders including investors, start-ups, industry, professional services companies and business associations. AusBiotech and its members had the opportunity to hear about the latest updates on the innovation and technology initiatives in Hong Kong, as well as discuss issues that they face in an interactive roundtable discussion. With more than 100 people in attendance, the day included a business luncheon themed ‘Hong Kong's advantages as an innovation and technology hub’, which included a keynote and Q&A with Mr Chan, and a panel discussion with fintech scaleups and technology investors. The roundtable discussion, themed ‘The development of Health Technology in Australia and Hong Kong as an innovation hub for global expansion’, explored opportunities for Australian healthtech innovators looking to expand key Asian markets like Hong Kong, and partnering with Hong Kong businesses and investors to develop commercial biomedical products, and recognised the strength of Australian innovation in this field. This roundtable provided an excellent opportunity for companies involved in the health and medical sector to understand first-hand the latest updates on the innovation and technology initiatives in Hong Kong, as well as the support available from the Hong Kong Government for foreign investors. Thank you to our members who participated in the roundtable, including: 360biolabs, a BioAgilytix company’s Sharon S., AdAlta Ltd’s (ASX:1AD) Tim Oldham, Chimeric Therapeutics' (ASX:CHM) Rebecca McQualter, and EZZ Life Science Holdings ASX:EZZ's Glenn Cross. Read more in the AusBiotech story here: https://lnkd.in/dx5xKbSN

🚀 Exciting Opportunity for Growth Equities Investors! 🚀 Join Glenn Cross, Chairman of EZZ Life Science Holdings ASX:EZZ, and other exciting companies at the F1 Aussie Equities Day on 20th September 2024 at Marina Bay Sands Expo & Convention Centre. This is your chance to gain insights, network, and explore new investment opportunities in the equities market. Don’t miss out on this exclusive event! 👉 RSVP now: tinyurl.com/ausequitiesday Proudly organised by Spark Plus & event partners: Invest and Trade Western Australia, iKeep, Anadara Asset Management & The Stock Network

EZZ Life Science Holdings ASX:EZZ's Director of Corporate Affairs James Hudson sat down with ACY Securities' Ashley Jessen to discuss EZZ's recent financial results, acquisition plans, US market entry and more. https://lnkd.in/gN89f-Y9